☆ 4.5 Article

Development of DNA Aptamer-Based PROTACs That Degrade the Estrogen Receptor

ACS MEDICINAL CHEMISTRY LETTERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Chemistry, Medicinal

Inducible Degradation of Oncogenic Nucleolin Using an Aptamer-Based PROTAC

Miao Chen et al.

Summary: By exploiting aptamers as targeting warheads, we developed a strategy for inducible degradation of undruggable proteins, thereby inhibiting cancer cell proliferation. To reduce on-target toxicity, we further developed a light-controllable PROTAC that can release the targeting warhead through UV irradiation, leading to target activation and degradation.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

添加到收藏夹

Letter Oncology

Selective degradation of the p53-R175H oncogenic hotspot mutant by an RNA aptamer-based PROTAC

Lingping Kong et al.

CLINICAL AND TRANSLATIONAL MEDICINE (2023)

添加到收藏夹

Meeting Abstract Oncology

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Xin Gao et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Biotechnology & Applied Microbiology

PROTAC targeted protein degraders: the past is prologue

Miklos Bekes et al.

Summary: Targeted protein degradation (TPD) is a new therapeutic modality that can tackle disease-causing proteins which are difficult to target with conventional small molecules. PROTAC molecules, utilizing the ubiquitin-proteasome system to degrade target proteins, has achieved clinical proof-of-concept and attracted significant industry activity. Future directions include identifying target classes suitable for TPD, expanding the use of ubiquitin ligases for precision medicine, and extending the modality beyond oncology.

NATURE REVIEWS DRUG DISCOVERY (2022)

添加到收藏夹

Article Chemistry, Medicinal

Development of Chimeric Molecules That Degrade the Estrogen Receptor Using Decoy Oligonucleotide Ligands

Miyako Naganuma et al.

Summary: Targeted protein degradation using chimeric small molecules like PROTACs and SNIPERs has gained attention, but developing degraders without suitable small-molecule ligands for target proteins is challenging. A new chimeric molecule, LCL-ER(dec), selectively degrades ER alpha via a click reaction, showing promise for the development of other oligonucleotide-type degraders targeting various transcription factors.

ACS MEDICINAL CHEMISTRY LETTERS (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope

Sinan Ma et al.

Summary: The article introduces the development of proteolysis targeting chimeras (PROTACs) technology and the advantages of non-small molecule PROTACs (NSM-PROTACs), and summarizes the progress of NSM-PROTACs so far.

ACTA PHARMACEUTICA SINICA B (2022)

添加到收藏夹

Article Oncology

ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.

Erika P. Hamilton et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin

Lin Zhang et al.

Summary: In this study, a novel PROTAC ZL216 was developed by using nucleic acid aptamer AS1411 as a targeting ligand of nucleolin and conjugating it with a small molecule ligand of E3 ligase VHL, achieving selective degradation of breast cancer cells. This study broadens the methods of constructing PROTACs and provides a promising strategy for tumor-selective therapy.

MOLECULAR THERAPY-NUCLEIC ACIDS (2022)

添加到收藏夹

Article Chemistry, Medicinal

Nucleic-Acid-Based Targeted Degradation in Drug Discovery

Wei Wang et al.

Summary: Targeted protein degradation (TPD) using proteolysis-targeting chimera (PROTAC) is a novel therapeutic modality in drug discovery, limited to protein targets with ligandable sites. The development of nucleic-acid-based modalities has expanded the scope of TPD, allowing for the degradation of nucleic acid targets. Ribonuclease-targeting chimera (RIBOTAC), a new type of chimeric RNA degrader, shows promising features in drug discovery.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Insights into the binding mode of AS1411 aptamer to nucleolin

Lihua Bie et al.

Summary: This study proposes a feasible binding mode for the recognition of cell surface nucleolin by AS1411 aptamer and provides atomic-level descriptions for its high affinity and specific binding. The molecular basis of this specific binding is elucidated, which can guide the rational design of AS1411-based aptamers.

FRONTIERS IN MOLECULAR BIOSCIENCES (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Nanodelivery of nucleic acids

Barbara B. Mendes et al.

Summary: There is a growing need for a safe and effective method to deliver gene therapy materials, and nanomaterials offer an unprecedented opportunity to overcome these challenges. By utilizing their diverse physico-chemical properties, nanomaterials can be functionalized to selectively target specific biomolecules. The combination of gene therapies and nanoscale delivery systems has expanded the therapeutic and biomedical applications of nucleic acid therapeutics.

NATURE REVIEWS METHODS PRIMERS (2022)

添加到收藏夹

Review Chemistry, Multidisciplinary

PROTACs: past, present and future

Ke Li et al.

Summary: PROTACs are a type of molecules with novel event-driven mechanism, offering multiple advantages over traditional inhibitors, such as catalytic nature and targeted protein degradation, which may lead to improved therapeutic outcomes with reduced toxicity. However, further research and development efforts are needed to fully explore their potential.

CHEMICAL SOCIETY REVIEWS (2022)

添加到收藏夹

Review Nanoscience & Nanotechnology

Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications

Shuaijian Ni et al.

Summary: Aptamers, with oligonucleotide sequences, have capabilities to bind to specific target molecules and are attracting great attention in diverse clinical translations. They offer advantages such as prolonged storage life and feasibility of chemical modifications for enhancing stability.

ACS APPLIED MATERIALS & INTERFACES (2021)

添加到收藏夹

Review Chemistry, Analytical

SELEX-based DNA Aptamer Selection: A Perspective from the Advancement of Separation Techniques

Shingo Saito

Summary: This review discusses the advancements in separation techniques for SELEX-based aptamer selection developed in this decade, including CE, microfluidic chip, solid phase, and FACS-based SELEX among others.

ANALYTICAL SCIENCES (2021)

添加到收藏夹

Review Chemistry, Medicinal

Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges

Shenxin Zeng et al.

Summary: PROTAC is a novel drug discovery paradigm that targets proteins for degradation. ARV-110, an orally small molecule PROTAC designed for Androgen receptor, has entered clinical trials, marking a new avenue for PROTAC development.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer

Shipeng He et al.

Summary: The aptamer-PROTAC conjugation strategy shows potential in improving the tumor-specific targeting ability and in vivo antitumor potency of conventional PROTACs, paving the way for the design of tumor-specific targeting PROTACs.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

TF-PROTACs Enable Targeted Degradation of Transcription Factors

Jing Liu et al.

Summary: A new therapeutic platform TF-PROTAC has been developed with selectivity to degrade target TFs and demonstrate anti-proliferative effects in cells. This platform holds promise as a universal strategy for targeting undruggable TFs.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG

Jingwei Shao et al.

Summary: DNA-binding proteins, such as transcription factors (TFs), are crucial in cellular processes and disease pathogenesis, but are difficult to target therapeutically due to their lack of enzymatic catalytic sites. PROTAC technology involves engineering bifunctional molecules to induce degradation of target proteins through ubiquitination. O'PROTACs, which incorporate a TF-recognizing double-stranded oligonucleotide, have been shown to effectively degrade cancer-related transcription factors like LEF1 and ERG, inhibiting cancer cell growth both in vitro and in vivo. These programmable O'PROTACs show promise as a tool for targeting various TFs for disease treatment.

ADVANCED SCIENCE (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Systematic Evolution of Ligands by Exponential Enrichment Technologies and Aptamer-Based Applications: Recent Progress and Challenges in Precision Medicine of Infectious Diseases

Yixin Xu et al.

Summary: This review provides a comprehensive overview of the latest development of SELEX technology and focuses on the applications of aptamer-based technologies in infectious diseases, such as targeted drug-delivery, treatments, and biosensors for diagnosing. The challenges and the future development in this field of clinical application will also be discussed.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Therapeutic applications of AS1411 aptamer, an update review

Rezvan Yazdian-Robati et al.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2020)

添加到收藏夹

Article Cell Biology

A PROTAC peptide induces durable β-catenin degradation and suppresses Wnt-dependent intestinal cancer

Hongwei Liao et al.

CELL DISCOVERY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer

Danhui Ma et al.

THERANOSTICS (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Recent Advances in Aptamer Discovery and Applications

Yang Zhang et al.

MOLECULES (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

First targeted protein degrader hits the clinic

Asher Mullard

NATURE REVIEWS DRUG DISCOVERY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells

Josue Carvalho et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Aptamer chemistry

Pascal Rothlisberger et al.

ADVANCED DRUG DELIVERY REVIEWS (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor degradation

Nobumichi Ohoka et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine

Zhenjian Zhuo et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)

Nobumichi Ohoka et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2017)

添加到收藏夹

Article Medical Laboratory Technology

DNA aptamer probes for detection of estrogen receptor α positive carcinomas

Arghya Sett et al.

TRANSLATIONAL RESEARCH (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs

John Hines et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Identification of RNA Aptamer Specific to Mutant KRAS Protein

Sujin Jeong et al.

OLIGONUCLEOTIDES (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.